Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 | Q14654 | 9/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994509 | 1.00 | KCNJ11 (0.34) | KCNJ11P2RX7KCNQ3KCNQ2 | |
| SCHEMBL16994496 | 0.88 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL17271388 | 0.88 | KCNJ11 (0.34) | KCNJ11KCNQ3KCNQ2 | |
| SCHEMBL16994505 | 0.88 | KDM4E (0.37) | KCNJ11P2RX7KCNQ3KCNQ2 | |
| SCHEMBL9901986 | 0.85 | JAK2 (0.33) | — | |
| SCHEMBL16994491 | 0.85 | JAK2 (0.33) | — | |
| SCHEMBL16994487 | 0.83 | KCNJ11 (0.33) | KCNJ11 | |
| SCHEMBL17271391 | 0.83 | KCNJ11 (0.33) | KCNJ11 | |
| SCHEMBL16994485 | 0.82 | P2RX7 (0.43) | KCNJ11P2RX7 | |
| SCHEMBL9901674 | 0.82 | FPR2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | KCNJ11 99/4885P2RX7 412/4885KCNQ3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.